Meeting
2013 ASCO Annual Meeting
Primary tumor location and expression of mir-664 as a combined biomarker for bevacizumab effectiveness in metastatic colorectal cancer.
Authors
Mogens Karsboel Boisen
Department of Oncology, Herlev Hospital, Copenhagen University Hospital, Copenhagen, Denmark
Mogens Karsboel Boisen , Christian Dehlendorff , Dorte Linnemann , Jim S. Larsen , Kell Oesterlind , Joergen Hansen , Svend Erik Nielsen , Per Pfeiffer , Line Schmidt Tarpgaard , Niels Henrik Hollander , Nina Keldsen , Torben Hansen , Brita Bjerregaard Jensen , Estrid Vilma Solyom Hoegdall , Benny Vittrup Jensen , Julia S. Johansen
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Colorectal) Cancer
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Colorectal Cancer
Citation
J Clin Oncol 31, 2013 (suppl; abstr 3572)
DOI
10.1200/jco.2013.31.15_suppl.3572
Abstract #
3572
Poster Bd #
5F
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Gastrointestinal Cancers Symposium
BREAKWATER: Randomized phase 3 study of encorafenib (enco) + cetuximab (cet) ± chemotherapy for first-line treatment (tx) of BRAF V600E-mutant (BRAFV600) metastatic colorectal cancer (mCRC).
First Author: Scott Kopetz
Poster
2021 ASCO Annual Meeting
BREAKWATER: Randomized phase 3 study of encorafenib (enco) + cetuximab (cetux) ± chemotherapy for first-line (1L) treatment (tx) of BRAF V600E-mutant (BRAFV600E) metastatic colorectal cancer (mCRC).
First Author: Scott Kopetz
Poster
2016 Gastrointestinal Cancers Symposium
MAVERICC, a phase 2 study of mFOLFOX6-bevacizumab (BV) vs FOLFIRI-BV with biomarker stratification as first-line (1L) chemotherapy (CT) in patients (pts) with metastatic colorectal cancer (mCRC).
First Author: Heinz-Josef Lenz
Poster
2014 Gastrointestinal Cancers Symposium
Bevacizumab (BEV) plus chemotherapy (CT) continued beyond first disease progression (PD) in patients with metastatic colorectal cancer (mCRC) previously treated with BEV-based therapy: Outcomes according to KRAS status and first-line CT backbone in the ML18147 study.
First Author: Stefan Kubicka